An Open Label Study of CM-AT for the Treatment of Children With Autism
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, open label extension study evaluating the continued safety and efficacy
of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.